Release Date: April 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you share the Medicare Advantage cost trend estimate for 2025 and how it compares to 2024? A: Andrew Witty, CEO, explained that the company anticipated care levels consistent with 2024. However, they observed a twofold increase in care activity in Q1 2025, particularly in physician and outpatient services. Timothy John Noel, CEO of UnitedHealthcare Medicare & Retirement, added that they expect this trend to persist throughout 2025 and into 2026, shaping their pricing assumptions.
Q: How does the higher incidence of primary care visits relate to Optum Health's performance, and why is value-based care still a strategic focus? A: Andrew Witty, CEO, noted that Optum Health and UnitedHealthcare operate different models. Amar Desai, CEO of Optum Health, highlighted that new value-based patients were less engaged by prior plans, impacting performance. Heather Bresch, an unidentified company representative, emphasized that value-based care offsets trends by engaging patients early, reducing emergency visits, and improving outcomes, supporting long-term growth.
Q: What are the key elements to return to UnitedHealth's long-term growth rate? A: Andrew Witty, CEO, expressed confidence in returning to the long-term growth rate, citing improved 2026 rates and the end of the transition period of absorbing pricing pressure. He emphasized addressing second-order effects seen in 2025 and fixing issues to deliver stronger performance in 2026.
Q: What is UnitedHealth's stance on PBM reform and Medicaid funding cuts? A: Patrick Conway, CEO of Optum Health, highlighted UnitedHealth's transparency and affordability initiatives, including commercial rebate pass-through and cost-based reimbursement for pharmacies. Krista Nelson, CEO of UnitedHealthcare Community & State, emphasized their broad footprint and confidence in supporting states through changes, focusing on member health and coverage access.
Q: How is UnitedHealth addressing the impact of tariffs on pharmaceuticals? A: Andrew Witty, CEO, stated that while the situation is dynamic, UnitedHealth feels well-positioned due to price protection mechanisms in contracts and legislation limiting manufacturers' ability to pass price increases. They are monitoring developments and will adjust bids thoughtfully.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。